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Abstract: Osteosarcoma is the most common primary malignant tumor of bone. The disease, 
however, is very rare with less than 2,000 expected patients at all age groups per year within the 
European Union and the United States of America. With multimodal therapy, which combines 
multiagent chemotherapy and complete resection of all macroscopically detectable tumors, about 
60%–70% of patients with localized osteosarcoma can be cured. The prognosis, however, is 
still poor for patients with synchronous or metachronous metastatic or nonresectable primary 
disease, with reported 5-year event-free survival (EFS) rates of less than 30%. Overall, the 
EFS rate has been rather stable since the introduction of combination chemotherapy including 
doxorubicin, cisplatin, high-dose methotrexate with leukovorin rescue, and/or ifosfamide. Mifa-
murtide, a modulator of innate immunity, which activates macrophages and monocytes, which 
in turn release chemicals with potential tumoricidal effects, may help to control microscopic 
metastatic disease and has been safely given together with standard adjuvant chemotherapy to 
patients with high-grade osteosarcoma. Results of the recently published intergroup study 0133 
trial from the Children’s Cancer and Pediatric Oncology Groups suggest that mifamurtide is a 
medicine that deserves further investigation in this orphan disease.
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Introduction
Osteosarcoma is the most common primary malignant tumor arising in bone. The 
incidence varies with age, and the Surveillance, Epidemiology and End Results 
(SEER) program of the National Cancer Institute provides the following osteosarcoma 
incidence data for the United States: 0–24 years, 4.4 cases per million per year; 25–59 
years, 1.7 cases per million per year; and $60 years, 4.2 cases per million per year.1 
Similar data have been reported for Europe.2 There are two peaks in incidence: the first 
one during the pubertal skeletal growth spurt (15–19 years, 8.2 cases per million per 
year) and the second one during old age (75–79 years, 6 cases per million per year); 
and the latter is attributed to the sarcomatous transformation of Paget disease of bone 
and other benign bone lesions.1 A rare or orphan disease affects fewer than 5 people 
per 10,000; therefore, osteosarcoma has been named an ultraorphan disease.3 Given 
a population of about 385 million people in the European Union (EU) and 307 mil-
lion people in the United States, less than 2,000 patients are expected to be diagnosed 
with osteosarcoma per year within the EU and the United States, and more than half 
of these patients are younger than 20 years.
Up to 20% of patients with osteosarcoma present with clinically detectable meta-
static disease at diagnosis (synchronous metastases).4 It is assumed, however, that about Therapeutics and Clinical Risk Management 2010:6 submit your manuscript | www.dovepress.com
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90% of patients will have subclinical microscopic metastatic 
disease at the time of diagnosis of osteosarcoma.
The management of patients with osteosarcoma is com-
plex and aims to completely remove all clinically detectable 
tumors surgically and control microscopic metastatic disease 
via systemic polychemotherapy. Complete surgical resection 
of all clinically detectable tumors is an essential prerequisite 
for long-term survival, and a complete remission can be 
achieved in up to 90% of patients with newly diagnosed 
osteosarcoma during frontline therapy.5 The use of inten-
sive neoadjuvant and adjuvant chemotherapy has improved 
relapse-free survival rates in patients with localized extremity 
tumors from less than 20% with surgery only, to about 70% 
with a combination of surgery and multiagent chemotherapy.6 
Despite aggressive multimodal treatment, patients having 
synchronous and metachronous metastatic disease with local 
relapse and nonresectable primary disease still have poor 
outcomes with survival rates of less than 30%.4,5,7,8
Surgical techniques have improved during the last 
decades, and there has been a successful shift from amputa-
tions toward limb-salvage surgery in neoadjuvant osteo-
sarcoma trials.6 However, this progress in surgery did not 
significantly improve survival.
There are currently 4 chemotherapeutic agents with well-
established efficacy in treating osteosarcoma: doxorubicin, 
cisplatin, high-dose methotrexate with leucovorin rescue, and 
ifosfamide. Since the introduction of standard chemotherapy 
regimens that include these drugs, the overall survival (OS) 
rates are stable, and no new drugs with proven efficacy have 
been added into the standard therapeutic armamentarium.
The immunomodulator mifamurtide (liposomal muramyl 
tripeptide phosphatidyl ethanolamine [L-MTP-PE] or 
MEPACT®; Takeda Pharmaceutical Company Limited 
[Osaka, Japan] and Millennium: The Takeda Oncology 
Company [Cambridge, MA]), which activates macrophages 
and monocytes, has been safely given together with standard 
adjuvant chemotherapy in high-grade osteosarcoma patients 
aged between 2 and 30 years and has been reported to improve 
outcome in this ultraorphan disease.
Exhaustive, excellent reviews on mifamurtide and 
osteosarcoma are available for readers who seek detailed 
information.3,9–11 This article briefly reviews the use of 
mifamurtide in the treatment of patients with osteosarcoma, 
including a short discussion on the development of the 
concept of immunotherapy of cancer and the immunology 
of L-MTP-PE and a discussion on whether the current 
knowledge and data are robust enough to universally adopt 
the cost-intensive treatment with mifamurtide as standard 
of care for patients with osteosarcoma in the industrialized 
world.
From Coley’s toxins to mifamurtide
More than 100 years ago, the bone sarcoma surgeon William 
Coley established the concept of immunotherapy of cancer 
by demonstrating that the infection produced by the injection 
of streptococcal organisms into a patient with cancer caused 
shrinkage of the malignancy. However, Coley’s results were 
controversial, and the used endotoxins or bacterial products 
sometimes led to lethal side effects. With the advent of radio-
therapy and chemotherapy, interest in Coley’s mixed toxins 
waned. The concept that the immune system could be triggered 
by endotoxins or bacterial products to kill tumor cells had, 
however, been rediscovered, particularly in malignant diseases 
that do not respond sufficiently to conventional treatments.
It was found that not endotoxins or bacterial products 
themselves but factors released by the host’s immune system 
(eg, macrophages) in response to the endotoxins or bacterial 
products can promote tumor necrosis, and one of the first 
identified factors was named tumor necrosis factor (TNF). 
Several other factors, collectively named cytokines and 
chemokines (secreted proteins with growth, differentiation 
and activation functions that regulate the nature of immune 
responses), were identified to promote toxic effects on 
tumor cells. Moreover, the receptors for these molecules 
and their intracellular signaling transduction pathways 
(such as the nuclear factor-kappaB [NF-κB], the mitogen-
activated protein kinases [MAPKs], the adaptor protein-1, 
and caspase 3 pathways) – which can promote cell survival, 
apoptosis, or inflammation reactions depending on the 
  cellular context – have been identified.12
In parallel, research on innate immunity revealed 
that immunity against microbes relies on the specific 
host-receptor detection of pathogen- and danger-derived 
molecular signatures by macrophages and monocytes, with 
the subsequent activation of cellular signaling pathways 
such as NF-κB and MAPK pathways, which can promote 
inflammation and release of antimicrobial peptides. These 
pattern-recognition molecules encompass several families 
including the toll-like receptor (TLR) and the nucleotide-
binding and oligomerization domain (NOD)-like receptors 
(NLRs such as NOD1, NOD2, and NLRP3).13 NOD1 and 
NOD2 comprise a subfamily of NLRs, which recognize 
distinctive core motifs within the peptidoglycan polymer 
in the cell wall of bacteria and possess an aminoterminal 
caspase recruitment domain, which is required to trigger 
NF-κB signaling.13Therapeutics and Clinical Risk Management 2010:6 submit your manuscript | www.dovepress.com
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The intracellular pattern-recognition molecule NOD2 
detects the pattern of muramyl dipeptide (MDP), a motif pres-
ent in all gram-positive and gram-negative bacterial walls.13 
Mifamurtide (L-MTP-PE) is a fully synthetic lipophilic 
derivate of MDP, and therefore, it is most likely also a ligand 
and an activator of NOD2 and other targets of MDP.3 NOD2 
has a tissue-specific expression pattern, and its expression is 
mainly restricted to monocytes, macrophages, dentritic cells, 
and intestinal Paneth cells.14 Recognition of MDP by NOD2 
mainly results in the production of proinflammatory cytokines 
like interleukin-1β (IL-1β), interleukin-6 (IL-6), and TNF-α, 
and other molecules (eg, chemokines, antimicrobial peptides, 
adhesion molecules, etc) whose expression is under the control 
of NF-κB.13 Moreover, MDP activates NLRP3, which is an 
essential component of the inflammasome, a protein complex 
that promotes the cleavage of procaspase 1 into its active 
form.15 Active caspase 1 in turn is essential to activate proin-
flammatory cytokines like IL-1β. Overall, activation of NLRs 
in macrophages and monocytes via MDP (or L-MTP-PE?) 
results in inflammation, release of antimicrobial peptides, 
fever, dendritic cell recruitment, polarization of T-helper cells, 
and promotion of bactericidal and potential tumoricidal effects. 
A scheme that depicts the possible mechanism of action of 
L-MTP-PE is provided in Figure 1.
Pharmacology of mifamurtide
The MDP molecule was found to be too pyrogenic and 
arthrogenic to be pharmacologically used in humans. Efforts 
focused on the development of less pyrogenic derivates, and 
in the early 1980s, L-MTP-PE was developed. The inter-
national nonproprietary name of the drug is mifamurtide. 
Mifamurtide, also called L-MTP-PE, is a liposomal formula-
tion of the active ingredient MTP-PE, which is a fully syn-
thetic, less pyrogenic, and longer-acting derivative of MDP.3 
The liposomal encapsulation of MTP-PE has been shown 
to strongly enhance the tumoricidal effects of MTP-PE via 
macrophage activation in vitro.16 Moreover, there is evidence 
that liposomal encapsulated MTP-PE is about 10 times less 
toxic than MTP-PE.17 The molecular structure of L-MTP-PE 
is provided in Figure 2.
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Figure 1 Possible mechanisms of action of L-MTP-Pe (for details, see text). 
Abbreviations: L-MTP-Pe, liposomal muramyl tripeptide phosphatidyl ethanolamine; MAPK, mitogen-activated protein kinases; NF-κB, nuclear factor-kappaB; NLRP3, 
nucleotide-binding and oligomerization domain (NOD)-like receptor P3; NOD2, nucleotide-binding and oligomerization domain 2; iL-1β, interleukin 1β.Therapeutics and Clinical Risk Management 2010:6 submit your manuscript | www.dovepress.com
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Pharmacokinetics
After intravenous (IV) infusion, mifamurtide is cleared very 
rapidly from plasma in cancer patients and in healthy adults, 
and the liposomes are mainly phagocytosed by the cells of 
the reticuloendothelial system (RES).3 In a biodistribution 
investigation in patients with osteosarcoma,  99mTc-labeled 
L-MTP-PE was found 6 hours after IV infusion in liver, 
spleen, nasopharynx, thyroid, and, to a lesser extent, in the 
lung, and this distribution pattern is consistent with that of 
the RES.18 Of note, in 2 of 4 patients with osteosarcoma 
lung metastases, radioactivity was detected at the site of 
the metastases.18 There is no evidence of accumulation of 
L-MTP-PE or free MTP-PE.19 More details on the pharma-
cokinetics of L-MTP-PE are available at the Web site of 
the European Medicines Agency (EMA) (http://www.ema.
europa.eu/humandocs/PDFs/EPAR/mepact/H-802-PI-en.
pdf; accessed 10.03.2010) and in an excellent recent review 
by Dr Paul Meyers.3
Pharmacodynamics
In animal studies, L-MTP-PE was found to be most effec-
tive against microscopic metastases but not against bulky 
disease.20,21 However, the exact mechanism by which 
L-MTP-PE induces a tumoricidal effect on osteosarcoma 
micrometastases is unknown. L-MTP-PE most likely acti-
vates macrophages and monocytes via the same signaling 
pathways as does MDP (ie, recognition via NOD2 and 
NLRP3 and activation of NF-κB, MAPKs, the inflammsome, 
etc), and the net effect can be the release of cytokines, 
proinflammatory molecules, etc, which have the potential 
to destroy tumor cells. In patients with osteosarcoma and 
healthy adults, it is well documented that within hours after 
L-MTP-PE was given, plasma levels of proinflammatory 
molecules, such as TNF-α, IL-6, and IL-1β, and other indi-
cators of immune stimulation like C-reactive protein and 
neopterine were elevated.3,22,23 Clinically, a cytokine flu with 
fever, chills, and rigors can be observed due to the release of 
these proinflammatory molecules, especially after the initial 
administration(s) of L-MTP-PE, before the development of 
tolerance.3
It is noteworthy that proinflammatory cytokines, such 
as IL-1β, IL-6, and TNF-α, have different roles in cancer, 
and they can be associated with fatigue, depression, cogni-
tive impairment, cachexia, anorexia, and pain (all of which 
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negatively affect the quality of life). They can influence 
the metabolism of certain anticancer drugs by acting on 
cytochrome P450 enzymes and can lead to the activation of 
NF-κB, which enables the survival of certain cancer cells and 
provides a mechanism by which they might become resistant 
to chemotherapy and radiotherapy.24 Clinical investigations, 
however, suggest that L-MTP-PE might result in a net posi-
tive effect in patients treated for osteosarcoma.3,25
Mifamurtide and osteosarcoma
The extremely rare phenomenon of spontaneous regression 
of malignancies is often associated with feverish infections.26 
Results from a recent investigation on osteosarcoma sug-
gested increased survival for patients who experienced deep 
postoperative infections.27 In this retrospective analysis, 
41 patients who developed a deep infection within 1 year 
after the implantation of a graft had 10-year survival rate of 
84.5%, compared with 62.3% in the cohort of 338 patients 
who did not have a deep infection.27 Clearly, these results 
have to be interpreted with caution. They are, however, of 
interest, especially in the context of immunotherapy for 
osteosarcoma.
The rationale behind the use of L-MTP-PE in osteosar-
coma treatment is to mimic a kind of infection that can help 
to eradicate residual micrometastases that are not eliminated 
by adjuvant chemotherapy. A landmark investigation in dogs 
provided first evidence that L-MTP-PE may be useful in 
the treatment of osteosarcoma.28 Osteosarcoma in dogs has 
many similarities to that in humans, and dogs with spontane-
ous osteosarcoma had improved disease-free survival when 
treated after surgery with L-MTP-PE when compared with 
dogs receiving placebo.28 The results from this randomized 
study and subsequent investigations in dogs and other ani-
mals prompted clinical studies in humans.3,29,30
Clinical investigations with mifamurtide  
in patients with osteosarcoma
A phase I clinical trial with L-MTP-PE was carried out in 
37 patients with advanced cancer, and the optimum IV dose 
was found to be in the range of 1–4 mg/m2 twice weekly for 
4 weeks – a dose that was well tolerated.31
A phase II clinical trial using L-MTP-PE was under-
taken in patients with osteosarcoma (aged 9–59 years) and 
synchronous or metachronous lung metastases to determine 
whether L-MTP-PE therapy could improve the progression-
free interval in this high-risk group of patients.32 After a 
complete surgical remission was achieved, a dosage of 
2 mg/m2 L-MTP-PE was infused over a 1-hour period twice 
a week for 12 weeks in 1 group of 12 patients (24 doses). 
The second group of 16 patients received 2 mg/m2 L-MTP-PE 
twice a week for 12 weeks, then once a week for an addi-
tional 12 weeks for a total of 24 weeks of therapy (36 doses). 
Relapse-free survival in these 2 groups was compared with a 
matched historical   control group (21 patients with metachro-
nous lung metastases, who received adjuvant chemotherapy); 
patients who received 24 weeks of L-MTP-PE therapy 
had a prolongation in time to relapse (9 months compared 
with 4.5 months for the historical control group), but those 
who received 12 weeks of therapy did not.32 Although the 
comparison with a historical control group does not allow 
definitive conclusions, these data suggested that L-MTP-PE 
deserved further investigation in patients with osteosarcoma 
in a more appropriate adjuvant setting. Of note, there was 
no evidence that L-MTP-PE therapy caused an acceleration 
of relapse, and toxic reactions were limited to chills, fever, 
headache, myalgias, and fatigue, which were especially com-
mon during the first administration. Subsequent administra-
tions yielded minimal or no toxic effects, except for delayed 
fatigue (grade 1).32
In this phase II trial, additional biological investiga-
tions were performed. For example, in 5 patients, a single 
osteosarcoma metastasis recurred within 6 weeks after the 
completion of L-MTP-PE therapy. The nodules were removed, 
and the specimens were compared with lung metastasis speci-
mens obtained before L-MTP-PE therapy. After L-MTP-PE 
therapy in 3 patients, peripheral fibrosis surrounded the lung 
metastasis, and inflammatory cell infiltration and neovascu-
larization were present. This is in contrast to lung metastases 
removed following chemotherapy, which showed central 
necrosis with viable peripheral tumor cells and no signs of 
inflammatory response. In the fourth case, evidence of early 
fibrotic changes was found. This and the fifth case showed a 
change in malignant characteristics, from high grade before 
L-MTP-PE therapy to low grade after therapy. Based on the 
results in these 5 patients, it was concluded that there is evi-
dence for a biological effect of L-MTP-PE on osteosarcoma 
lung metastases.22
In a subsequent phase IIb trial, the tolerability of 
L-MTP-PE given in combination with ifosfamide was inves-
tigated in 9 patients with osteosarcoma and lung metastases.33 
It was demonstrated that the simultaneous administration of 
an immunostimulator (ie, L-MTP-PE) and a cytotoxic agent 
(ie, ifosfamide) was safe and did not cause an increase in 
toxicity or obliteration of the immune response.33
The results of the trials described earlier prompted a 
phase III randomized prospective trial, the intergroup (INT) Therapeutics and Clinical Risk Management 2010:6 submit your manuscript | www.dovepress.com
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study 0133 from the Children’s Cancer (CCG 7921) and 
Pediatric Oncology (POG 9351) Groups (now merged to the 
Children’s Oncology Group [COG]), in patients with newly 
diagnosed osteosarcoma aged #30 years.
intergroup study 0133 (CCG 7921  
and POG 9351)
This largest ever completed randomized trial in   osteosarcoma 
was conducted from 1993 to 1997 and recruited a total 
of 662 patients with nonmetastatic osteosarcoma whose 
primary tumors were considered to be resectable.25 In addi-
tion, 91 patients with primary metastatic osteosarcoma were 
recruited and also analyzed.34
In INT 0133, all patients were intended to receive a simi-
lar backbone treatment (high-dose methotrexate with leuco-
vorin rescue + doxorubicin/adriamycin + cisplatin = MAP) 
with identical cumulative doses of high-dose methotrexate 
(12 times at doses of 12 g/m2), doxorubicin (6 times at doses 
of 75 mg/m2), and cisplatin (4 times at doses of 120 mg/m2).
The randomized prospective study was conducted with a 2 × 2 
factorial design with 4 treatment arms: (1) arm A− consisting 
of MAP, (2) arm A+ consisting of MAP + L-MTP-PE, (3) 
arm B− consisting of MAP + ifosfamide, and (4) arm B+ 
consisting of MAP + ifosfamide + L-MTP-PE. Ifosfamide 
was given 5 times at a dose of 9 g/m2 per course. L-MTP-PE 
was given at a dose of 2 mg/m2, and the dose was escalated 
up to 2 mg/m2 + 2 mg if no biological activity (ie, cytokine 
flu) was observed after the first administration. L-MTP-PE 
was administered IV twice weekly for 12 weeks beginning 
at week 12 and then weekly for additional 24 weeks begin-
ning at week 24. The duration of treatment was 20 weeks for 
patients randomly assigned to arm A−, 27 weeks for patients 
randomly assigned to arm B−, and 36 weeks for patients 
randomly assigned to arm A+ and arm B+.25,35
The results of INT 0133 were analyzed after different 
observation durations and published in 2005 and 2008.25,35 In 
the first analysis, Meyers et al35 identified event-free   survival 
(EFS) as the primary outcome measure and reported a sig-
nificant interaction between the L-MTP-PE and ifosfamide 
with respect to the primary end point EFS.36 Moreover, no 
significant impact of L-MTP-PE on EFS was identified.35 
The focus on EFS in this initial report was later quoted as an 
error, and in the subsequent analysis with longer follow-up, 
OS and EFS were reported as the end points of the study.25 
This reanalysis with longer follow-up reported improved 
survival with the addition of L-MTP-PE to chemotherapy 
(pooled analysis) from 70% to 78% 6-year OS (P = 0.03; 
relative risk, 0.73).25 In the analysis of EFS, a P-value of 
0.102 for the test of interaction was interpreted as sufficient 
evidence of no interaction, and the pooled analysis of EFS 
was also carried out.25 However, only very large interactions 
could be detected, so a borderline P value – as presented 
herein for EFS – should not be interpreted as evidence of no 
interaction.36 An unpooled analysis of EFS showed a strong 
difference between treatment without and with L-MTP-PE 
for arm B and almost identical outcomes with and without 
L-MTP-PE for arm A. Thus, the pooled analysis could have 
produced estimates of L-MTP-PE treatment effects that were 
either too large or too small, depending on whether ifosf-
amide was present. For OS, there was less evidence for an 
interaction and a borderline significant effect of L-MTP-PE 
(P = 0.03) in the pooled analysis. Overall, the effect of treat-
ment on OS is expected to be mediated through EFS, and 
this, amongst other issues, makes the interpretation of the 
results of INT 0133 very difficult (for details, see Hunsberger 
et al36 and Bielack et al37). In the cohort of patients with pri-
mary metastatic osteosarcoma, the addition of L-MTP-PE 
to chemotherapy did not achieve a statistically significant 
improvement in the outcome.34 There was, however, a trend 
toward better outcomes in patients with synchronous metas-
tases treated with L-MTP-PE, but the low number of patients 
analyzed precluded clear conclusions.
Clinical safety
Almost all patients (and healthy volunteers) treated with 
L-MTP-PE experienced chills, fever, headache, myalgias, and 
fatigue, especially during the first administration.3,10 These 
adverse drug reactions, however, decreased in intensity and 
were often no longer observed in subsequent administrations. 
Caution must be noted in patients with pre-existing asthma, 
as these patients can develop mild to moderate respiratory 
distress associated with treatment. Other concerns include 
hearing loss and delayed fatigue. Exhaustive data on the 
safety and tolerability of L-MTP-PE are available at the Web 
site of the EMA (http://www.ema.europa.eu/humandocs/
PDFs/EPAR/mepact/H-802-PI-en.pdf; accessed March 10, 
2010).
Regulatory status
MEPACT (L-MTP-PE) has recently received marketing 
authorization in the EU by the EMA, whereas no approval has 
yet been provided by the US Food and Drug Administration 
in the United States. In Europe, based on the assessment of 
more than 80 studies, the Committee for Medicinal Products 
for Human Use suggested that the benefits of MEPACT are 
greater than its risks when used in combination with adjuvant Therapeutics and Clinical Risk Management 2010:6 submit your manuscript | www.dovepress.com
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chemotherapy to treat high-grade resectable nonmetastatic 
osteosarcoma after the complete macroscopic surgical 
resection. The committee recommended that MEPACT be 
given marketing authorization, and the European Com-
mission granted a marketing authorization for MEPACT, 
valid throughout the EU, on March 6, 2009 (detailed 
report   available at http://www.ema.europa.eu/humandocs/
PDFs/EPAR/mepact/H-802-PI-en.pdf; accessed March 10, 
2010), to be used as adjuvant to polychemotherapy for the 
postoperative treatment of patients (aged 2–30 years) with 
nonmetastatic high-grade resectable osteosarcoma after the 
complete macroscopic resection.
Expected costs of the treatment 
with MEPACT
MEPACT is currently produced by Takeda and is avail-
able since 2010 for clinical use in certain countries 
(eg,   Germany and Austria). The cost for one vial contain-
ing 4 mg L-MTP-PE will be around €3,000. The agent 
is intended to be given 48 times at a dose of 2 mg/m2, 
and the estimated costs of the drug alone for the treat-
ment of 1 patient in   Germany are about €110,000,00 for 
children and €150,000,00 for adults (http://www.akdae.
de/30/10/50/2009004-Mepact.pdf). Overall, this would 
probably approximately double the costs for the treatment 
of a patient with osteosarcoma.
Summary
Based on the available preclinical and clinical data, 
L-MTP-PE is an agent that deserves further investiga-
tion to define its role in the treatment of osteosarcoma. 
  However, considerable debate about whether the addition 
of L-MTP-PE to standard chemotherapy regimens as an 
adjuvant in the treatment of patients with high-grade osteo-
sarcoma truly results in an unequivocally proven benefit 
is still ongoing, and as outlined above, the results of the 
randomized prospective clinical trial INT 0133 did not suf-
fice to resolve this debate.36,37 The investigators of INT-0133 
state that they did not discuss or advocate any specific use 
of L-MTP-PE, but that they think it is important to place 
L-MTP-PE into some perspective.38 Lead investigators of 
the largest osteosarcoma study groups and the National 
Institute of Health agree that L-MTP-PE is an agent that 
warrants additional investigation before it can be consid-
ered for routine use in the frontline therapy of patients with 
high-grade osteosarcoma.37 Therefore, future international 
prospective trials should further investigate L-MTP-PE in 
osteosarcoma.
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